These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 14610521)

  • 21. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics.
    Hamdani N; Bonnière M; Adès J; Hamon M; Boni C; Gorwood P
    Neurosci Lett; 2005 Mar; 377(1):69-74. PubMed ID: 15722190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [No association of -1438G/A polymorphism in promoter region of 5-HT2A receptor gene with antipsychotic agent-induced weight gain].
    Mou XD; Zhang ZJ; Yao ZJ; Liu W; Zhang XR; Shi JB; Sun J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Oct; 22(5):575-6. PubMed ID: 16215954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: a pilot study.
    Dursun SM; Patel JK; Burke JG; Reveley MA
    J Psychiatry Neurosci; 1999 Sep; 24(4):333-7. PubMed ID: 10516800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonin receptor 2A gene polymorphisms and schizophrenia: association with family history, diagnostic subtype and height in patients.
    Melkersson K; Hulting AL
    Neuro Endocrinol Lett; 2009; 30(3):343-51. PubMed ID: 19855357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India.
    Kaur G; Gupta D; Chavan BS; Sinhmar V; Prasad R; Tripathi A; Garg PD; Gupta R; Khurana H; Gautam S; Margoob MA; Aneja J
    Asian J Psychiatr; 2017 Oct; 29():174-182. PubMed ID: 28692863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
    Himei A; Okamura T
    Psychiatry Clin Neurosci; 2005 Oct; 59(5):556-62. PubMed ID: 16194258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
    Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
    Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
    Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
    Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study.
    Zhao QZ; Liu BC; Zhang J; Wang L; Li XW; Wang Y; Ji J; Yang FP; Wan CL; Xu YF; Feng GY; He L; He G
    Psychiatr Genet; 2012 Dec; 22(6):298-9. PubMed ID: 22935916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Huang CH; Tsai GE
    J Clin Psychopharmacol; 2008 Feb; 28(1):64-8. PubMed ID: 18204343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia.
    Zahari Z; Teh LK; Ismail R; Razali SM
    Psychiatr Genet; 2011 Aug; 21(4):183-9. PubMed ID: 21206399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
    Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
    J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications.
    Weickert TW; Goldberg TE; Mishara A; Apud JA; Kolachana BS; Egan MF; Weinberger DR
    Biol Psychiatry; 2004 Nov; 56(9):677-82. PubMed ID: 15522252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-acting risperidone improves negative symptoms in stable psychotic patients.
    Curtis VA; Katsafouros K; Möller HJ; Medori R; Sacchetti E
    J Psychopharmacol; 2008 May; 22(3):254-61. PubMed ID: 18308804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia.
    Kang SG; Lee HJ; Choi JE; Park YM; Park JH; Han C; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
    Neuropsychobiology; 2008; 57(1-2):49-54. PubMed ID: 18451638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
    Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
    J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study.
    Angelucci F; Bernardini S; Gravina P; Bellincampi L; Trequattrini A; Di Iulio F; Vanni D; Federici G; Caltagirone C; Bossù P; Spalletta G
    J Alzheimers Dis; 2009; 17(1):203-11. PubMed ID: 19494443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.